Clinical Trial Update: Study With Dual Therapy Including Lamivudine (300 mg QD) Plus Raltegravir (1200 mg QD) in Virologically Suppressed HIV-1 Infected Patients Experiencing Inconvenience, Toxicity, Negative Impact on Co-morbidities or Risk of Drug-drug Interactions With Their Current Regimen [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating a dual therapy of lamivudine and raltegravir in virologically suppressed HIV-1 patients has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Epivir (Lamivudine)
• Isentress (Raltegravir)

Snippet

Sponsor: Judit Pich | Conditions: HIV Seropositivity, HIV Infections | Phase 3 | Status: TERMINATED